Pulmonology

How the LAMA therapy manages one of the integral facets of COPD care.

While one disease is benefitting from advancing digital screening measures, the other has a standard therapy which could provide benefit to both.

A new study finds the months of January-March are most burdened with COPD exacerbation-based hospitalizations, mortality, and hospital costs.

How should physicians navigate the public belief that vaping is less harmful than cigarette smoking?

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.

How the aclidinium bromide trial brings novel perspective to COPD care.

Asthma burden among women can vary based on their age. Are there varying methods of care?

Are diagnostics and drugs optimized for pulmonary hypertension?

Fewer than 2% of all patients hospitalized with pneumonia in 2014 received the vaccination.

The chronic respiratory disease is often under-diagnosed in female patients.

New ASCENT-COPD data show the therapy's benefit in reducing cardiovascular events among high-risk patients, along with significant exacerbation reduction.

The fixed-dose therapy was shown to reduce exacerbations, regardless of patient history, among those with increased cardiovascular risk.

What the introduction of aclidinium/formoterol could mean for patients with COPD.

The approved label update now indicates the therapy delays disease progression when used in combination with an approved oral background PAH therapy.

A new assessment from CHRONICLE study data show patient-reported assessment on disease control may be more accurate.

The drug class has become a mainstay in clinical practice and treatment plans. But could it reach greater, and wider, indications?

Investigators found similar rescue treatment use among patients who do and do not have frequent exacerbations.

A study observing the effect of formulary changes to children with asthma show FEV and FEF scores worsened significantly when switching inhaler types.

The most recent CDC data, presented at CHEST 2019, show nearly 1500 patients have reported an associated lung injury, and 33 have died.

A new study shows adult e-cigarette use in the US was steadily dropping since 2014— before spiking in 2018 among adults aged 18-24 years.

The geko device is designed to increase blood circulation and edema reduction to prevent venous thrombosis in non-surgical patients.

The United States Food and Drug Administration has accepted a BLA for Viaskin Peanut from DBV Technologies for the treatment of peanut-allergic children ages 4 to 11, which previously withdrew a BLA in 2018 after request from the FDA requested additional data on its manufacturing procedures and quality controls.

The indication makes it the first respiratory biologic available either at home or in a professional setting, with eight-week maintenance dosing.

Trelegy Ellipta could become the first triple-combination, single-inhaler therapy approved for the treatment of both asthma and COPD.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.